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ORIGINAL ARTICLE
Reduced Dopamine Receptor Sensitivity
as an Intermediate Phenotype in Alcohol
Dependence and the Role of the COMT Val158Met
and DRD2 Taq1A Genotypes
Arnt F. A. Schellekens, MD; Barbara Franke; Bart Ellenbroek, PhD; Alexander Cools, PhD; Cor A. J. de Jong, MD, PhD;
Jan K. Buitelaar, MD, PhD; Robbert-Jan Verkes, MD, PhD
Context: Alcohol dependence is a common neuropsy-
chiatric disorder with high heritability. However, ge-
netic association studies on alcohol dependence are of-
ten troubled by nonreplication. The use of intermediate
phenotypes may help make clear the mode of action of
various candidate genes and improve the reproducibil-
ity of genetic association studies.
Objective: To test central dopamine receptor sensitiv-
ity as an intermediate phenotype for alcohol depen-
dence, specifically evaluating the hypothesis that the do-
paminergic genes COMT Val158Met and DRD2 Taq1A
affect dopamine receptor sensitivity.
Design: Case-control pharmacogenetic challenge study.
Setting: Patients with alcohol dependence admitted for
detoxification were compared with healthy control sub-
jects matched for age and level of education.
Participants: Patients (n=110) were a consecutive
sample, whereas controls (n=99) were recruited through
advertisements in regional newspapers.
Intervention: A dopamine challenge test was subcuta-
neously administered using the dopamine agonist apo-
morphine hydrochloride (0.005 mg/kg).
Main Outcome Measures: Outcome measures were
plasma growth hormone levels and results of a continu-
ous performance task.
Results: Central dopamine receptor sensitivity is
reduced in alcohol dependence, and this is modulated
by dopaminergic genes. Specifically, DRD2 Taq1A
genotype affected dopamine receptor sensitivity as
measured by plasma growth hormone levels, and
COMT Val158Met genotype affected dopamine recep-
tor sensitivity as measured by performance on a con-
tinuous performance task. In a logistic regression
analysis, reduced dopamine receptor sensitivity on
both measures predicted alcohol dependence, without
an additive effect of the COMT Val158Met and DRD2
Taq1A genotypes.
Conclusions: COMT Val158Met and DRD2 Taq1A may
affect the intermediate phenotype of central dopamine
receptor sensitivity.COMTVal158Met andDRD2 Taq1A
may confer their risk of alcohol dependence through re-
duced dopamine receptor sensitivity in the prefrontal cor-
tex and hindbrain, respectively.
Arch Gen Psychiatry. 2012;69(4):339-348
A LCOHOL DEPENDENCE ISconsidered a chronic re-lapsing neuropsychiatricdisorder with a multifac-torial origin.1,2 Heritabil-
ity estimates are as high as 60%, with many
genes explaining only a fraction of the heri-
tability.3,4 Attempts to delineate genetic
contributions have met with limited suc-
cess. There is an ongoing search for inter-
mediate phenotypes in alcohol depen-
dence to aid in genetic research.5-11
Fundamental to the concept is the as-
sumption that variation in an intermedi-
ate phenotype depends on variation of
fewer genes than in the more complex dis-
ease phenotype and is therefore more trac-
table in genetic analysis.11 In a recent ar-
ticle, a plea was made to adhere to
intermediate phenotypes known to be in-
volved in the pathogenesis of a disorder
to minimize the risk of pleiotropic find-
ings.9 The selection of an intermediate phe-
notype should then be based on conver-
gent evidence among various studies from
human epidemiologic investigations, ex-
perimental neuroscience, and animal re-
search.12
In alcohol dependence, evidence from
various lines of research indicates that al-
terations in at least 2 dopamine pathways
are involved in the pathogenesis.1,13-15 The
first is the mesolimbic dopamine path-
way, often referred to as the reward path-
Author Affiliations are listed at
the end of this article.
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way. Alcohol generates its reinforcing effect by increasing
the firing rate of dopamine neurons in the ventral tegmen-
tal area, leading to enhanced dopamine activity in the ven-
tral striatum.16 Reduced densities of striatal dopamine re-
ceptors have been observed in patients with alcohol
dependence.1,14 Reduced sensitivity to the dopamine ago-
nist apomorphine hydrochloride, indexed by the growth
hormone (GH) response, has repeatedly been observed in
patients with alcohol dependence.17-21 Among individuals
with addiction, reduced dopamine receptor sensitivity is
thought to decrease the sensitivity to naturally occurring
reinforcers. This may increase vulnerability to the devel-
opment of alcohol abuse because alcohol consumption
would compensate for this reward deficiency.1,13,14,21-23
The second dopamine pathway involved in alcohol de-
pendence runs from the ventral tegmental area to the pre-
frontal cortex (PFC), often referred to as the inhibitory con-
trol pathway.14,24,25 Individuals who abuse drugs show lower
glucose metabolism in the PFC.1,14 Moreover, patients with
alcohol dependence seem to be less sensitive to the effects
of the dopamine agonist apomorphine as measured by the
performance of tasks requiring PFC functioning.20 It has
been suggested that PFC and mesolimbic dopamine recep-
tor dysfunction is interrelated, resulting in a double handi-
cap in alcohol dependence, including deficient reward pro-
cessing and behavioral control.1,14,26,27
Based on this evidence, the measurement of dopa-
mine receptor sensitivity using a challenge with a dopa-
mine agonist may disclose a useful phenotype for ge-
netic studies of alcohol dependence.28 Indeed, studies in
animals and humans have shown that variation in dopa-
mine receptor sensitivity is highly heritable29-31 and pre-
dicts self-administration of substances such as cocaine
and alcohol.15,30 Yet, genetic studies using this dynamic
intermediate phenotype are scarce.
The dopamine receptor D2 gene (DRD2; OMIM
*126450) and its genetic polymorphism Taq1A
(rs1800497) are among the most extensively studied ge-
netic variants in alcohol dependence. Some studies32,33
have shown that the DRD2 Taq1A genotype is associ-
ated with a 30% reduction in dopamine receptor den-
sity in the striatum of healthy volunteers. Meta-
analyses34-36 have shown an increased risk of alcohol
dependence for carriers of theA1 allele, although the odds
ratios are small (range, 1.22-1.90). Some studies have
tested the role of the DRD2 genotype in in vivo dopa-
mine receptor sensitivity measured by the GH response
to the dopamine agonist apomorphine. In patients with
alcohol dependence, a genotype in linkage disequilib-
rium with the Taq1A genotype (AA genotype) has been
found to be associated with reduced GH response to apo-
morphine.37 However, most studies18,37-39 failed to show
such an association for the DRD2 Taq1A genotype itself.
Several issues with respect to these studies should be taken
into consideration. First is the frequent low statistical
power. Sample sizes vary between 18 and 97 partici-
pants, with only the latter representing enough power
to detect any genotype effect.18,38,39 Second is the ab-
sence of a group of healthy control subjects in most dopa-
mine challenge investigations.18,38 It has been suggested
that genes for which expression is altered by chronic ex-
cessive alcohol intake encode proteins that affect apo-
morphine-induced GH release.38,40 Any association be-
tween genes and dopamine receptor sensitivity in patients
with alcohol dependence should be confirmed in a healthy
control group. Third is the timing of measurements with
respect to alcohol detoxification.18,38 Previous investiga-
tions have shown a strong influence of detoxification on
the GH response to apomorphine in patients with alco-
hol dependence.18 An intermediate phenotype should ide-
ally be independent of the state of the disorder (eg, in-
toxification or detoxification).7,9,11 In the only study19
that showed an association between DRD2 Taq1A and
reduced GH response to apomorphine, measurements
were performed on day 1 of detoxification among pa-
tients with alcohol dependence. Therefore, the useful-
ness of the GH response to apomorphine as an interme-
diate phenotype for alcohol dependence relative to
DRD2, including a healthy control group, has yet to be
confirmed in a substantially large sample after conclu-
sion of initial detoxification.
Another dopaminergic gene that has been frequently
studied in alcohol dependence is the catechol O-
methyltransferase gene (COMT; OMIM116790). The
COMT enzyme encoded by this gene metabolizes dopa-
mine, adrenalin, and noradrenalin and is the main fac-
tor controlling dopamine levels in the PFC. A common
functional single-nucleotide polymorphism in the cod-
ing region of COMT induces a valine to methionine sub-
stitution (Val158Met [rs4680]) and is associated with a
40% reduction in enzyme activity.41,42 The COMT geno-
type affected reactivity to the administration of dopa-
mine agonists among healthy volunteers in tasks that rely
on PFC functioning.43 The COMT genotype has been as-
sociated with subtypes of alcohol dependence, with a
higher frequency of the Met allele in patients with type
1 alcohol dependence (ie, early-onset alcohol depen-
dence with presumed high heritability).44-46 However,
negative association results have also been reported.47-50
Therefore, the COMT genotype is a notable candidate to
study relative to the effects of apomorphine on cogni-
tive task performance in alcohol dependence.
The present study was designed to assess the func-
tional consequences of risk alleles along the dopamine
pathway, as measured by plasma GH levels and results
of a continuous performance task after a challenge with
the dopamine agonist apomorphine, to disclose func-
tional in vivo intermediate phenotypes for alcohol de-
pendence. The hypotheses of the study were as follows:
(1) patients with alcohol dependence show reduced re-
activity to the dopamine agonist apomorphine com-
pared with healthy control subjects, (2) genetic varia-
tion in DRD2 and COMT affects the response to
apomorphine, and (3) dopamine receptor sensitivity is
a better predictor of alcohol dependence than the pres-
ence of dopaminergic addiction-related genes.
METHODS
PARTICIPANTS
In a case-control study design, a consecutive series of male pa-
tients with alcohol dependence (diagnosed according toDSM-IV
criteria) who were admitted to our detoxification clinic were
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compared with healthy male control subjects who were
matched for age and level of education. We selected only men
to avoid potential confounding effects of the menstrual cycle
on dopamine receptor functioning in women.51-55 In addition,
most patients with alcohol dependence in The Netherlands
who are admitted to a detoxification clinic are male. Controls
were recruited through advertisements in regional newspa-
pers. Exclusion criteria consisted of the following: non-Euro-
pean ancestry, language disabilities prohibiting written in-
formed consent, any medical condition interfering with
apomorphine administration (eg, allergy or recent cardiac dis-
ease), or current or past neuropsychiatric disorder related to
dysfunction of the dopamine system (eg, psychosis, Korsakoff
syndrome, or Parkinson disease). Controls with a history of
psychiatric disorder or a family history of psychiatric disorder
(including substance dependence) were excluded. In total,
110 patients and 99 controls were recruited. Table 1 gives
characteristics of both study groups, and the eFigure (http:
//www.archgenpsychiatry.com) shows a flowchart of the study
cohort selection.
To assess alcohol and drug dependence, we used section 4
of the Dutch version of the Addiction Severity Index.56 The Ad-
diction Severity Index is a reliable tool for the assessment of
alcohol and drug dependence in clinical samples.57,58 Lifetime
occurrence of Axis I disorders was assessed using version 2.1
of the Dutch Mini-International Neuropsychiatric Interview for
psychiatric disorders and the Dutch version of the ADHD (At-
tention-Deficit/Hyperactivity Disorder) Rating Scale.59-61
To avoid effects of nicotine and caffeine use or withdrawal,
participants were not allowed to smoke or consume caffeine-
containing drinks on the morning of testing for 2 hours before
measurements as assessed by self-report.62,63 Patients were tested
after 1 month of controlled abstinence based on daily self-
report and regular breath tests and after at least 1 week with-
out the use of benzodiazepines.
The study was approved by the regional medical ethical board
(Medisch-Ethische Toetsingscommissie Instellingen Geeste-
lijke Gezondheidszorg) (protocol 271, P04.0388L). All par-
ticipants gave written informed consent.
GENOTYPING OF COMT rs4680 GA (Val158Met)
AND DRD2 Taq1A rs1800497 CT
Blood samples were obtained by venipuncture, and DNA was iso-
lated using standard protocols. Molecular analyses were per-
formed in a CCKL (Centrale Commissie ter bevordering van de
Kwaliteit van Laboratorium onderzoek en de accreditatie van labo-
ratoria in de gezondheidszorg)–accredited laboratory at the De-
partmentofHumanGenetics,RadboudUniversityNijmegenMedi-
cal Centre, the Netherlands. The DRD2 Taq1A rs1800497 and
COMT rs4680 polymorphisms were genotyped using TaqMan-
based analysis.64 Genotyping was performed in a volume of 10
µL containing 10 ng of genomic DNA. For DRD2, 5 µL of Taq-
Man Mastermix (2; Applied Biosystems), 0.125 µL of TaqMan as-
say (TaqMan assay: C_7486676_10, reporter 1, VIC-A-allele, re-
verse assay; Applied Biosystems), and 3.875 µL of water were
added. ForCOMT, 5 µL of ABgene Mastermix (2, ABgene Ltd),
0.125 µL of TaqMan assay (TaqMan assay: C_25746809_50, re-
porter 1, VIC-A-allele; Applied Biosystems), and 3.875 µL of wa-
ter were added. Amplification was performed on a commercially
available system (7500 Fast Real-Time PCR, Applied Biosys-
tems), starting with 15 minutes at 95°C, followed by 50 cycles of
15 seconds at 95°C and 1 minute at 60°C. Genotypes were scored
using the algorithm and software supplied by the manufacturer
(Applied Biosystems).
To investigate the random genotyping error rate in the 2 as-
says, the laboratory included 5% duplicate DNA samples, which
showed 100% consistency in genotype. In addition, 4% blanks
were included, which were all negative.
APOMORPHINE CHALLENGE
Central dopamine receptor sensitivity was measured using a
challenge with subcutaneous administration of the dopamine
Table 1. Demographic Characteristics Among Healthy Control Subjects and Patients With Alcohol Dependence
Characteristic
Control Subjects
(n=99)
Patients
(n=109)a Statistic P Value
Age, mean (SD), y 39 (9) 41 (11) F1,98=2.6 .11
Educational level, No. (%)b
None 1 (1.0) 4 (3.7)
2=5.1 .27
Basic 7 (7.1) 15 (13.8)
Low 41 (41.4) 46 (42.2)
Intermediate 34 (34.3) 28 (25.7)
High 16 (16.2) 16 (14.7)
Current substance use, No. (%)
Habitual smoking 42 (42.4) 73 (67.0) 2=14.0 .001
Habitual caffeine use 95 (96.0) 106 (97.2) 2=0.9 .34
Selective serotonin reuptake inhibitor use 3 (3.0) 11 (10.1) 2=4.1 .05
Psychiatric comorbidity, No. (%)
Depression NA 29 (26.6) 2=28.4 .001
Anxiety disorder NA 17 (15.6) 2=16.7 .001
Obsessive-compulsive disorder NA 2 (1.8) 2=1.8 .18
Attention-deficit/hyperactivity disorder NA 10 (9.2) 2=9.5 .002
Past comorbid substance use, No. (%)
Stimulants NA 11 (10.1) NA NA
Opioids NA 9 (8.3) NA NA
Cannabis NA 38 (34.9) NA NA
Hallucinogens NA 6 (5.6) NA NA
Abbreviation: NA, not applicable.
aFor 1 patient, the level of education was unknown.
bNone is primary school with no diploma, basic is secondary school, low is lower vocational education, intermediate is higher vocational education, and high is
higher professional education or university.
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agonist apomorphine hydrochloride (0.005 mg/kg). Outcome
measures were the neuroendocrine response as measured by
plasma GH levels and the effect on cognition as measured by
performance on a continuous performance task. Samples for
GH testing were obtained at baseline and at 30, 50, and 70 min-
utes after apomorphine administration; the cognitive task was
performed at baseline and at 20 and 40 minutes after apomor-
phine administration.
PLASMA APOMORPHINE
AND GH MEASUREMENTS
Blood samples (4 mL) were obtained to assess plasma apomor-
phine and GH levels. After centrifugation, samples of 2.0 mL
were kept on ice and stored at −30°C. Apomorphine levels were
assessed by high-pressure liquid chromatography with elec-
trochemical detection.65 Plasma GH levels were measured by
radioimmunoassay using an antiserum raised in guinea pig. One
patient was excluded from analysis because of a baseline GH
level above the detection limit of 1.6 ng/mL (to convert GH level
to micrograms per liter, multiply by 1.0). Before January 1, 2006,
we used the first (80/505) international standard for GH for
the standard curve, based on a batch of ampoules (coded 80/
505) containing highly purified pituitary human GH; begin-
ning January 1, 2006, the second (98/754) international stan-
dard was used. Within and between coefficients of variation
were 7.1% and 10.5%, 4.3% and 8.2%, and 5.4% and 10.9% at
levels of 6.0, 10.8, and 35.2 mIU/L, respectively, before and af-
ter January 1, 2006.
COGNITIVE TASK PERFORMANCE
MEASUREMENT
Cognition was assessed using the AX continuous performance
task (AX-CPT). This task consists of single letters consecu-
tively shown in white on a black screen with an interstimulus
interval of 1300 milliseconds as described previously.66 Par-
ticipants were instructed to give a target response (right-
button press) after the probe X appeared preceded by the cue
A or to give a nontarget response (left-button press) after any
other combination of letters. Responses were scored in a win-
dow between 100 and 2000 milliseconds after stimulus onset.
Two distracter letters were presented in red between the cue
and probe; 70% of the trials were target trials.66,67 The tasks lasted
10 minutes. To reduce learning effects, participants per-
formed a practice session before the 3 test sessions.
STATISTICAL ANALYSIS
Baseline differences in GH levels, cognitive task performance,
and demographic characteristics between patients and con-
trols and the 2 genotypes (DRD2 and COMT) were compared
using analysis of variance for continuous variables and 2 test
for categorical variables. Differences in response to apomor-
phine between groups (patient vs control and genotype) were
analyzed using repeated-measures analysis of variance, with AX-
CPT accuracy (percentage of commission errors) and plasma
GH levels as dependent variables, time as a within-subject vari-
able, and group (patient or control) and genotype (DRD2 or
COMT) as between-subject variables. For the DRD2 genotype,
2 groups were formed (A1 carriers vs A2/A2) owing to the few
A1 homozygotes. TheCOMT genotype was analyzed in 3 groups
(Val/Val, Val/Met, and Met/Met). To test for a gene dosage ef-
fect, we used special contrast analysis, testing the hypothesis that
the effect of apomorphine on cognitive task performance was twice
as strong in carriers of 2 Met allele copies than in carriers of 1
Met allele compared with those homozygous for the Val allele.
Because patients often were smokers, had psychiatric co-
morbidity, and used selective serotonin reuptake inhibitors, these
factors were added as covariates in the repeated-measures analy-
sis of variance. To protect an overall  level of .05, Bonferroni-
Holm correction was applied to the 4 independent tests, and
only adjusted P values are presented.
To analyze the prediction of alcohol dependence by geno-
type and intermediate phenotype, logistic regression analysis
was performed with group (patient or control) as the depen-
dent variable using the forced entry method. To test a model
of mediation, the intermediate phenotypes (maximum GH re-
sponse and maximum cognitive response to apomorphine) were
entered in block 1, and the genetic factors (DRD2 and COMT)
were added in block 2.
Data were analyzed using commercially available statisti-
cal software (SPSS, version 16.0; SPSS, Inc). Two-sided  =.05
was considered statistically significant.
RESULTS
BASELINE COMPARISON
Demographics of the study population are summarized
in Table 1. Patients more often were smokers, had psy-
chiatric comorbidity, and used serotonin reuptake in-
hibitors. The genotype frequencies did not deviate from
Hardy-Weinberg equilibrium (2=2.1, P=.16 for DRD2;
and2=0.7,P=.40 forCOMT). These are given in Table2
and are similar to those reported in other European
samples.68 There was no association of DRD2 Taq1A or
COMT Val158Met genotype with alcohol dependence.
At baseline, patients performed worse on the AX-CPT
(Table 3). Neither the DRD2 genotype nor the COMT
Table 2. Genotype Distribution Among Healthy Control Subjects and Patients With Alcohol Dependence
Genotype
%
2 Statistic P Value
Control Subjects
(n=99)
Patients
(n=110)
DRD2 Taq1A
A1/A1 1.0 1.8
0.5 .77A1/A2 29.3 31.8
A2/A2 69.7 66.4
COMT Val158Met
Val/Val 22.2 23.6
3.6 .15Val/Met 53.5 40.9
Met/Met 24.2 35.5
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genotype was associated with the baseline AX-CPT task
performance (the error percentages wereF2,95=1.1,P=.32
forDRD2 and F2,95=1.0, P=.38 forCOMT; reaction times
were F2,95=1.6, P=.21 for DRD2 and F2,95=0.7, P=.48 for
COMT).
EFFECTS OF APOMORPHINE ADMINISTRATION
There were no differences in apomorphine levels be-
tween genotype groups or between patients and con-
trols at any time point. These results are summarized in
Table 3.
Accuracy on the AX-CPT decreased after apomor-
phine administration (the error percentage wasF1.9,205=4.2,
P=.02) (Figure 1). Patients were less sensitive than con-
trols to the effects of apomorphine on AX-CPT accuracy
(F1.9,205=5.3,P=.005 for response to apomorphinegroup).
Carriers of 1 or 2 COMT Met alleles were more sensitive
than noncarriers of a Met allele to the detrimental effects
of apomorphine on AX-CPT accuracy, with homozygous
Met allele carriers being most sensitive (F3.8,205=3.1,P=.048
for response to apomorphineCOMT). The special con-
trast analysis for a gene dosage effect fell just short of being
significant (the contrast value was F4,205=0.061, P=.06).
There was no difference in the effect of the COMT geno-
type between patients and controls (F4,93=1.6, P=.17 for
response to apomorphineCOMTgroup). The DRD2
genotype did not affect sensitivity to the effect of apomor-
phine on AX-CPT accuracy (F1.6,205=0.5, P=.58 for re-
sponse to apomorphineDRD2).
Growth hormone levels increased after apomor-
phine administration (F1.6,205=104.6,P.001) (Figure2).
Patients showed decreased GH response to apomor-
phine compared with controls (F1.6,205=6.2, P .001 for
response to apomorphinegroup). Carriers of at least
1 DRD2 A1 allele had decreased GH response to apomor-
phine compared withDRD2A2homozygotes (F1.6,205=4.3,
P=.02 for response to apomorphineDRD2). There was
no difference between patients and controls in the effect
of the DRD2 genotype (F1.6,205=0.2, P=.88 for response
to apomorphineDRD2group). There was no differ-
ence in GH response among the 3 COMT genotypes
Table 3. Endophenotype Measures in Response to Apomorphine Hydrochloride Administration Among Healthy Control Subjects and
Patients With Alcohol Dependence
Variable
Mean (SD)
F Score
P
Value
Control
Subjects
(n = 99)
Patients
(n = 110)
Plasma growth hormone level, ng/mL (n = 87)
Baseline 0.5 (1.7) 0.6 (2.0) F1,195 = 0.3 .60
30 min 25.7 (25.7) 14.4 (22.4) F1,195 = 10.8 .001
50 min 27.0 (21.1) 21.1 (19.4) F1,195 = 4.1 .045
70 min 20.0 (18.1) 16.5 (15.2) F1,195 = 2.1 .15
Apomorphine level (n = 92) (n = 90)
10 min 1.59 (0.94) 1.48 (1.22) F1,180 = 0.5 .48
30 min 0.80 (0.64) 0.94 (0.65) F1,180 = 2.4 .12
50 min 0.50 (0.51) 0.60 (0.34) F1,180 = 2.5 .11
Error percentage on AX-CPT task
Baseline 3.0 (0.3) 7.4 (0.7) F1,207 = 29.4 .001
20 min 5.1 (0.6) 7.2 (0.9) F1,207 = 4.0 .046
40 min 4.9 (0.6) 7.0 (0.9) F1,207 = 4.0 .047
Reaction time on AX-CPT task, ms
Baseline 330 (58) 406 (130) F1,207 = 28.4 .001
20 min 350 (90) 412 (146) F1,207 = 13.2 .001
40 min 350 (84) 410 (121) F1,207 = 17.4 .001
Abbreviation: AX-CPT, AX continuous performance task.
SI conversion factor: To convert growth hormone level to micrograms per liter, multiply by 1.0.
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Figure 1. Effect of the COMT genotype (COMT Val158Met) on the cognitive
endophenotype (AX continuous performance task [AX-CPT] response to
apomorphine hydrochloride administration) in healthy control subjects and
in patients with alcohol dependence. Among controls and patients, carriers
of the COMT Met/Met genotype made more errors on the AX-CPT after
apomorphine administration. The deterioration in AX-CPT response after
apomorphine administration was less in carriers of a COMT Val allele at both
20 minutes (F2,205=6.5, P=.01) and 40 minutes (F2,205=3.1, P=.049).
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(F3.1,205=0.4, P= .90 for response to apomorphine
COMT).
PREDICTION OF ALCOHOL DEPENDENCE
Results of the logistic regression analyses are summa-
rized in Table 4. Growth hormone response and cog-
nitive task performance after administration of the dopa-
mine agonist predicted alcohol dependence (2=17.1,
P .001 for the block 1 model [62.3% of participants were
correctly predicted]). Adding DRD2 and COMT to the
model did not significantly improve the prediction of al-
cohol dependence (2=1.3, P=.52 for the block 2 model
[63.2% of participants were correctly predicted]). The
total variance explained by the model was 11%
(Nagelkerke R2). Interaction between genotypes and in-
termediate phenotypes was not significant.
COMMENT
To our knowledge, this is the first study showing added
value of apomorphine sensitivity as an intermediate phe-
notype in alcohol dependence. As predicted by our first
hypothesis, the plasma GH level response and the dis-
ruptive effect on cognitive task performance after apo-
morphine administration were reduced in patients hav-
ing alcohol dependence compared with healthy controls.
These findings are in line with previous studies20,21,69
among smaller samples of patients with alcohol depen-
dence. Our findings confirm the presence of reduced dopa-
mine receptor sensitivity in patients with alcohol depen-
dence, even after initial detoxification. Patients herein
performed worse on the AX-CPT at baseline compared
with controls. Although the data show that perfor-
mance among patients with alcohol dependence can de-
teriorate further after administration of apomorphine, de-
pending on theCOMT genotype, a potential ceiling effect
could not be ruled out completely.
In line with our second hypothesis, dopaminergic al-
cohol dependence genes affected central dopamine re-
ceptor sensitivity. The DRD2 genotype specifically in-
fluenced apomorphine effects on plasma GH levels. These
findings suggest that the DRD2 genotype is mainly re-
lated to subcortical dopamine receptor functioning. Pre-
vious investigations have shown that the DRD2 geno-
type is associated with reduced dopamine receptor density
in the striatum, although this was not always repli-
cated.33 Because GH response is a marker for neuroin-
fundibular dopamine receptor function, our data sug-
gest that dopamine receptor density may also be reduced
in the neuroinfundibulum in carriers of theDRD2Taq1A
genotype. Whether the neuroinfundibular response to
apomorphine is related to striatal dopamine receptor den-
sity is unknown.
The DRD2 Taq1A genotype is part of a gene cluster
neighboring the ANKK1 gene cluster.70-72 Other genes
within these clusters have been shown to be potential risk
genes for alcohol dependence.73 Moreover, a study19
among a small sample of patients with alcohol depen-
dence showed an association of theANKK1 genotype with
the apomorphine-induced GH response.
The COMT genotype affected the response to apo-
morphine as measured by the AX-CPT. Because the
AX-CPT requires PFC dopamine receptor functioning,
this suggests that COMT is particularly relevant to PFC
dopamine.74-77 Our observations may be explained by the
inverted-U hypothesis on PFC dopamine receptor func-
tioning and cognitive task performance, indicating that
both too high and too low levels of PFC dopamine are
related to worse cognitive performance. Carriers of the
COMT Val/Val genotype are presumed to have reduced
PFC dopamine receptor functioning due to more effi-
cient clearance of synaptic dopamine.78 Suboptimal PFC
dopamine levels at baseline may be compensated for by
dopamine receptor stimulation after apomorphine ad-
ministration. However, in carriers of 1 or 2 Met alleles,
administration of apomorphine may “overshoot” dopa-
mine receptor stimulation and reduce cognitive task
performance. Therefore, the effect of a phasic shift in dopa-
mine levels on cognitive task performance after admin-
istration of a dopamine agonist may be dependent on tonic
variation in dopamine levels based on variation in the
COMT genotype.43 Future studies are needed to further
confirm the inverted-U hypothesis.
In line with our third hypothesis, dopamine receptor
sensitivity was a better predictor of alcohol dependence
than the COMT or DRD2 genes. This shows that adding
dopamine receptor sensitivity as an intermediate phe-
notype is a crucial step to find alcohol dependence–
related risk genes. Prior evidence79,80 has suggested that
the COMT genotype may be involved in impulsivity and
affective processing. Impairment of executive control in
carriers of the COMT Val/Val genotype may be associ-
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Figure 2. Effect of the DRD2 genotype (DRD2 Taq1A) on the neuroendocrine
endophenotype (plasma growth hormone response to apomorphine
hydrochloride administration) in healthy control subjects and in patients with
alcohol dependence. Among controls and patients, the DRD2 genotype
affects the response to apomorphine, with carriers of a DRD2 A1 allele
showing a blunted response, particularly at 30 minutes (F1,205=6.5, P=.01 at
30 minutes; F1,205=3.7, P=.06 at 50 minutes; and F1,205=2.4, P=.12 at 70
minutes). In addition, patients show a blunted response at 30 minutes and at
50 minutes (F1,205=2.9, P .001 at 30 minutes; F1,205=5.2, P=.02 at 50
minutes; and F1,205=2.8, P=.10 at 70 minutes). To convert growth hormone
level to micrograms per liter, multiply by 1.0.
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ated with increased impulsivity or novelty seeking. How-
ever, a previous study81 did not find a correlation be-
tween apomorphine-induced GH response and personality
traits, such as novelty seeking. In addition, genetic varia-
tion in COMT has been suggested to be related to affec-
tive processing. This has been formulated in the tenta-
tive “warrior-worrier” model.79 In this model, the COMT
Met allele is hypothesized to be advantageous in memory
and attention tasks, whereas reactivity to unpleasant
stimuli is increased in COMT Met allele carriers.79,80 This
increased reactivity to unpleasant stimuli might cause a
lower emotional resilience against negative mood states
observed in individuals with a higher COMT Met158 al-
lele load (worrier strategy). Therefore, the COMT Met
allele seems to be beneficial during the performance of
working memory and attention-related tasks, whereas the
COMT Val allele may be advantageous during the pro-
cessing of aversive emotional stimuli (warrior strategy).
The effect of theCOMT genotype was similar across pa-
tients and controls. However, in patients with alcohol de-
pendence, improvement in cognitive task performance af-
ter apomorphine administration was seen in genotypes with
at least 1 COMT Val allele, whereas this was only the case
in homozygous COMT Val allele carriers among the con-
trols. Administration of apomorphine may be less likely to
result in dopamine receptor overstimulation in patients with
alcohol dependence. This suggests that PFC dopamine re-
ceptor functioning may be further reduced in patients with
alcohol dependence, consistent with a leftward shift of the
inverted-U curve in these individuals.
Although both genetic variants were associated with
dopamine receptor sensitivity, they were not predictive
of alcohol dependence. The sample size may have been
too small to detect an association with alcohol depen-
dence, although it was sufficient to show an association
with dopamine receptor sensitivity. This is consistent with
the idea that intermediate phenotypes are genetically less
complex and that their use can improve the validity of
genetic association studies.
The present findings may indicate a model of pleiot-
ropy or a causal model, with reduced dopamine recep-
tor sensitivity mediating the genetic risk for alcohol de-
pendence associated with the genotypes.7 However, in a
model of mediation, it is to be expected that adding
DRD2 and COMT to the regression model would not
improve the prediction of the model based on the inter-
mediate phenotypes alone, as is the case in the present
study. In addition, both clinical and preclinical litera-
ture on the role of dopamine receptor dysfunction in
the origin of alcohol dependence renders a model of
mediation plausible.2,14
Our results suggest that different genes confer their
effect on disease vulnerability through different biologi-
cal pathways. COMT specifically affected dopamine re-
ceptor sensitivity at the level of the PFC. This may in-
crease vulnerability to the development of alcohol
dependence through impaired response inhibition and
control.1 DRD2 Taq1A affected dopamine receptor sen-
sitivity in the hindbrain (neuroinfundibulum). Hind-
brain dopamine receptor sensitivity may be related to al-
terations in reward processing and increase the risk of
alcohol dependence.
These findings should be considered in the context
of strengths and limitations of our study design. Strengths
are that we used a functional intermediate phenotype of
alcohol dependence by measuring the response to apo-
morphine administration among a large sample after ini-
tial detoxification, including a healthy control group. Fur-
thermore, unlike previous studies using a challenge
paradigm with a dopamine agonist, we measured plasma
levels of the administered drug and found equal plasma
apomorphine levels among patients and controls. There-
fore, the differences found in the response to apomor-
phine between patients and controls and between the dif-
ferent genotype groups are likely true pharmacodynamic
differences. Previous studies have shown that AX-CPT
responses and plasma GH levels are stable under a pla-
cebo condition.28 Therefore, we considered it unneces-
sary to include a placebo condition in this larger-scale
study. However, particularly with respect to AX-CPT re-
sponses, a genotype effect on habituation or a learning
effect cannot be ruled out completely. It should be rec-
ognized that this study included men only. Additional
work is needed to examine whether these results can be
generalized to women.
It has been previously suggested that GH levels after
apomorphine administration normalize after 24 hours to
8 days of abstinence.17 In our study, challenge tests were
Table 4. Prediction of Alcohol Dependence Based on Response to Apomorphine Hydrochloride Administration
(Intermediate Phenotype) and Genotype
Factor Included
Block 1a Block 2b
 (SE)
P
Value OR (95% CI)  (SE)
P
Value OR (95% CI)
Intermediate phenotype
Maximum growth hormone response −0.02 (0.01) .008 0.98 (0.97-0.99) −0.02 (0.01) .009 0.98 (0.97-0.99)
Maximum AX-CPT response 0.06 (0.02) .01 1.06 (1.01-1.11) 0.06 (0.02) .01 1.06 (1.02-1.11)
Genotype
COMT Val158Met NA NA NA −0.23 (0.20) .26 0.80 (0.54-1.18)
DRD2 Taq1A NA NA NA −0.01 (0.31) .99 1.00 (0.54-1.84)
Abbreviations: AX-CPT, AX continuous performance task; NA, not applicable; OR, odds ratio.
aRegression analysis with only the intermediate phenotype as a predictor of alcohol dependence.
bRegression analysis with the intermediate phenotype and the genotype as predictors of alcohol dependence, showing no additive effect of the genotype
predictor.
ARCH GEN PSYCHIATRY/ VOL 69 (NO. 4), APR 2012 WWW.ARCHGENPSYCHIATRY.COM
345
©2012 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/23390/ by a Radboud University Nijmegen User  on 03/13/2017
performed after a mean of 30 days of abstinence. This
suggests that reduced response to apomorphine among
patients with alcohol dependence may represent a stable
intermediate phenotype. If true, future studies should
confirm reduced response to apomorphine among in-
dividuals at risk but without alcohol dependence (ie, un-
affected family members of patients with alcohol depen-
dence). Animal studies30 have shown that apomorphine
sensitivity is transmitted over generations, suggesting that
heritable factors are involved. However, up-to-date evi-
dence for heritability of apomorphine sensitivity in hu-
mans is lacking.18,30,31,38,82,83 In addition, scarring effects
of excessive alcohol consumption or prior detoxifica-
tion on the brain remain possible, persistently reducing
the sensitivity of the dopamine receptor system. Indeed,
findings in monkeys have shown that reduced dopa-
mine receptor densities in the brain are related to in-
creased self-administration of cocaine but that cocaine
administration itself further reduces dopamine receptor
densities.84 In the present study, it cannot be excluded
that reduced apomorphine sensitivity is partly a re-
sidual marker rather than an intermediate phenotype.
No neuroimaging measures were included herein. In-
stead of neuroimaging techniques, 2 functional mea-
sures were used based on previous findings using an apo-
morphine challenge paradigm. This has the advantage of
measuring functional outcome measures, with good timely
resolution. However, any interpretation about localiza-
tion of the observed effects should be considered within
this limitation. Clearly, the GH response is predomi-
nantly indicative of neuroinfundibular dopamine recep-
tor sensitivity, and the AX-CPT response is predomi-
nantly indicative of PFC dopamine receptor sensitivity.
However, the absence of an effect of COMT on the GH
response does not completely rule out that COMT ex-
erts an effect on other subcortical measures of dopa-
mine receptor sensitivity. Similarly, despite the absence
of an effect of DRD2 on the cognitive task performance,
DRD2 may affect cortical dopamine receptor sensitivity
when measured using different tasks.
It is likely that neurobiological pathways other than
the dopamine receptor system, and additional genetic
polymorphisms within those, have a role in the suscep-
tibility to alcohol dependence (eg, within the hypotha-
lamic-pituitary-adrenal axis or the opioid, glutamate, or
serotonergic systems). The relative contributions of other
such neurotransmitter systems in addition to central dopa-
mine receptor sensitivity remain to be studied.
In summary, the present study provides evidence that
(1) dopamine receptor sensitivity is lower in patients with
alcohol dependence than in matched healthy controls,
(2) dopamine receptor sensitivity is associated with do-
paminergic alcoholism-related genes, and (3) alcohol de-
pendence is more robustly associated with reduced dopa-
mine receptor sensitivity than with dopaminergic
genotypes. This study emphasizes the importance of using
dynamic or functional intermediate phenotypes in ge-
netic studies on alcohol dependence.
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